Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment.
Aged
Angiogenesis Inhibitors
/ therapeutic use
Diabetic Retinopathy
/ drug therapy
Female
Humans
Macula Lutea
/ physiology
Macular Edema
/ drug therapy
Male
Middle Aged
Recombinant Fusion Proteins
/ therapeutic use
Retina
/ pathology
Retinal Ganglion Cells
/ pathology
Retrospective Studies
Visual Acuity
/ physiology
Anti-VEGF
Conbercept
Diabetic macular edema
Layer segmentation
Retinal layer thickness
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
31 May 2019
31 May 2019
Historique:
received:
12
01
2019
accepted:
20
05
2019
entrez:
2
6
2019
pubmed:
4
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
To assess the changes in individual retinal layer thickness and visual function associated with gains in visual acuity after an intravitreal conbercept injection in the diabetic macular edema (DME) on spectral domain optical coherence tomography (SD-OCT) and microperimetry during 1-year follow-up. Retrospective observational study. Twenty patients with clinically significant DME in the study eye were imaged by SD-OCT every 3 months and MP1 microperimeter in the third month while receiving anti-vascular endothelial growth factor (VEGF) (conbercept) treatment. In each patient, seven retinal layers were segmented in 98 scans covering a 6 mm × 6 mm area of the macula at baseline and during 1 year of treatment. An automatic, full-threshold microperimetry of the central field (10° × 10°, 40 stimulated points) with the MP1 microperimeter. Thickness and microperimetry changes were quantitatively measured and evaluated for their correlation with increases in visual acuity. Although thicknesses of the inner nuclear layer (INL) and the outer nuclear layer (ONL) were reduced the most after treatment (p < 0.05), decreases of the ganglion cell layer (GCL) (r = 0.591, p = 0.006) and inner plexiform layer (IPL) (r = 0.663, p = 0.001) in central subfield area was associated with best-corrected visual acuity (BCVA) gain, and had the best estimation of BCVA gain (adjust R Neural recovery occurred after the resolution of edema during conbercept treatment, due to the decreases in GCL and IPL associating with gains in vision and improved microperimetry.
Sections du résumé
BACKGROUNDS
BACKGROUND
To assess the changes in individual retinal layer thickness and visual function associated with gains in visual acuity after an intravitreal conbercept injection in the diabetic macular edema (DME) on spectral domain optical coherence tomography (SD-OCT) and microperimetry during 1-year follow-up.
METHODS
METHODS
Retrospective observational study. Twenty patients with clinically significant DME in the study eye were imaged by SD-OCT every 3 months and MP1 microperimeter in the third month while receiving anti-vascular endothelial growth factor (VEGF) (conbercept) treatment. In each patient, seven retinal layers were segmented in 98 scans covering a 6 mm × 6 mm area of the macula at baseline and during 1 year of treatment. An automatic, full-threshold microperimetry of the central field (10° × 10°, 40 stimulated points) with the MP1 microperimeter. Thickness and microperimetry changes were quantitatively measured and evaluated for their correlation with increases in visual acuity.
RESULTS
RESULTS
Although thicknesses of the inner nuclear layer (INL) and the outer nuclear layer (ONL) were reduced the most after treatment (p < 0.05), decreases of the ganglion cell layer (GCL) (r = 0.591, p = 0.006) and inner plexiform layer (IPL) (r = 0.663, p = 0.001) in central subfield area was associated with best-corrected visual acuity (BCVA) gain, and had the best estimation of BCVA gain (adjust R
CONCLUSIONS
CONCLUSIONS
Neural recovery occurred after the resolution of edema during conbercept treatment, due to the decreases in GCL and IPL associating with gains in vision and improved microperimetry.
Identifiants
pubmed: 31151389
doi: 10.1186/s12886-019-1131-0
pii: 10.1186/s12886-019-1131-0
pmc: PMC6544971
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
KH902 fusion protein
1P05PW62F3
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Subventions
Organisme : National Natural Science Foundation of China
ID : 81470638
Organisme : China Association for Science and Technology
ID : 2016YFC0904800
Organisme : Shanghai Sailing Program
ID : 19YF1439300
Organisme : Shanghai Jiao Tong University Translation Medicine Cross Research Fund Project)
ID : ZH2018QNA24
Références
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):617-24
pubmed: 14744906
Am J Ophthalmol. 2005 Jan;139(1):18-29
pubmed: 15652824
Diabetes. 2005 Jun;54(6):1615-25
pubmed: 15919781
Br J Ophthalmol. 2007 Nov;91(11):1499-503
pubmed: 17504849
Ophthalmology. 2008 Aug;115(8):1366-71, 1371.e1
pubmed: 18675696
Ophthalmology. 2009 Jan;116(1):66-72
pubmed: 19118697
Ophthalmology. 2009 Oct;116(10):1949-59.e8
pubmed: 19699533
Ophthalmology. 2010 Aug;117(8):1571-6, 1576.e1
pubmed: 20472294
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Retina. 2011 Jan;31(1):48-55
pubmed: 20683379
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Retina. 2012 Jun;32(6):1087-99
pubmed: 22481473
Diabetes Obes Metab. 2013 Mar;15(3):224-33
pubmed: 22958404
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8154-61
pubmed: 23132803
Clin Ter. 2013;164(2):e121-6
pubmed: 23698213
Ophthalmology. 2013 Oct;120(10):2013-22
pubmed: 23706949
PLoS One. 2013 Aug 12;8(8):e70544
pubmed: 23950958
Ophthalmology. 2014 May;121(5):1045-53
pubmed: 24491642
Ophthalmology. 2014 Sep;121(9):1740-7
pubmed: 24793528
JAMA. 2014 Jun 11;311(22):2269-70
pubmed: 24915254
Invest Ophthalmol Vis Sci. 2014 Sep 23;55(10):6960-7
pubmed: 25249609
N Engl J Med. 2015 Mar 26;372(13):1193-203
pubmed: 25692915
Ophthalmology. 2015 Jul;122(7):1375-94
pubmed: 25935789
Ophthalmic Res. 2015;54(3):118-23
pubmed: 26315560
Retina. 2016 May;36(5):938-43
pubmed: 26630313
Retina. 2016 Jul;36(7):1314-23
pubmed: 26735563
Sci Rep. 2016 Dec 06;6:38326
pubmed: 27922068
Acta Ophthalmol. 2018 Mar;96(2):e195-e200
pubmed: 29063703
J Clin Invest. 1998 Aug 15;102(4):783-91
pubmed: 9710447